CAL
TCRR

Capital Advisors Ltd’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Capital Advisors Ltd’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-50
Closed – – 1633
2022
Q2 		$0 Sell
50
-249
-83% -$614 ﹤0.01% 1434
2022
Q1 		$1K Buy
+299
New +$941 ﹤0.01% 850

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Advisors Ltd's TCRR Position: Q3 2022 in Review

Capital Advisors Ltd sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 50 shares.

Capital Advisors Ltd first reported a position in TCRR in Q1 2022 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • Capital Advisors Ltd reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 50 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022.
  • Capital Advisors Ltd first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's TCR2 Therapeutics Inc. Common Stock position peaked at $1K in Q1 2022.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.